398 related articles for article (PubMed ID: 21270624)
1. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
Rustin GJ; Vergote I; Eisenhauer E; Pujade-Lauraine E; Quinn M; Thigpen T; du Bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J;
Int J Gynecol Cancer; 2011 Feb; 21(2):419-23. PubMed ID: 21270624
[TBL] [Abstract][Full Text] [Related]
2. Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
Zebic DS; Tjokrowidjaja A; Francis KE; Friedlander M; Gebski V; Lortholary A; Joly F; Hasenburg A; Mirza M; Denison U; Cecere SC; Ferrero A; Pujade-Lauraine E; Lee CK
Br J Cancer; 2024 Feb; 130(3):425-433. PubMed ID: 38097739
[TBL] [Abstract][Full Text] [Related]
3. When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
Oxnard GR; Morris MJ; Hodi FS; Baker LH; Kris MG; Venook AP; Schwartz LH
J Natl Cancer Inst; 2012 Oct; 104(20):1534-41. PubMed ID: 22927506
[TBL] [Abstract][Full Text] [Related]
4. Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.
Bagnoli M; Shi TY; Gourley C; Speiser P; Reuss A; Nijman HW; Creutzberg CL; Scholl S; Negrouk A; Brady MF; Hasegawa K; Oda K; McNeish IA; Kohn EC; Oza AM; MacKay H; Millan D; Bennett K; Scott C; Mezzanzanica D
Cells; 2019 Feb; 8(3):. PubMed ID: 30813545
[TBL] [Abstract][Full Text] [Related]
5. Optimal assessment of response in ovarian cancer.
Eisenhauer EA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii49-viii51. PubMed ID: 22180400
[TBL] [Abstract][Full Text] [Related]
6. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
Aghajanian C; Goff B; Nycum LR; Wang YV; Husain A; Blank SV
Gynecol Oncol; 2015 Oct; 139(1):10-6. PubMed ID: 26271155
[TBL] [Abstract][Full Text] [Related]
7. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
[TBL] [Abstract][Full Text] [Related]
8. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P;
Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483
[TBL] [Abstract][Full Text] [Related]
9. Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Lindemann K; Kristensen G; Mirza MR; Davies L; Hilpert F; Romero I; Ayhan A; Burges A; Rubio MJ; Raspagliesi F; Huizing M; Creemers GJ; Lykka M; Lee CK; Gebski V; Pujade-Lauraine E
Ann Oncol; 2016 Aug; 27(8):1505-10. PubMed ID: 27407100
[TBL] [Abstract][Full Text] [Related]
10. A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Stähle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MK; Oza AM;
N Engl J Med; 2011 Dec; 365(26):2484-96. PubMed ID: 22204725
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract][Full Text] [Related]
12. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
Herzog TJ; Vermorken JB; Pujade-Lauraine E; Provencher DM; Jagiello-Gruszfeld A; Kong B; Boman K; Park YC; Parekh T; Lebedinsky C; Gómez J; Monk BJ
Gynecol Oncol; 2011 Aug; 122(2):350-5. PubMed ID: 21546066
[TBL] [Abstract][Full Text] [Related]
13. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
14. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.
Lawrenson K; Iversen ES; Tyrer J; Weber RP; Concannon P; Hazelett DJ; Li Q; Marks JR; Berchuck A; Lee JM; Aben KK; Anton-Culver H; Antonenkova N; ; ; Bandera EV; Bean Y; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Chang-Claude J; Chenevix-Trench G; Chen A; Chen Z; Cook LS; Cramer DW; Cunningham JM; Cybulski C; Plisiecka-Halasa J; Dennis J; Dicks E; Doherty JA; Dörk T; du Bois A; Eccles D; Easton DT; Edwards RP; Eilber U; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goode EL; Goodman MT; Gronwald J; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall E; Hogdall C; Hosono S; Jakubowska A; Paul J; Jensen A; Karlan BY; Kjaer SK; Kelemen LE; Kellar M; Kelley JL; Kiemeney LA; Krakstad C; Lambrechts D; Lambrechts S; Le ND; Lee AW; Cannioto R; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; Nevanlinna H; McNeish I; Menon U; Modugno F; Moysich KB; Narod SA; Nedergaard L; Ness RB; Noor Azmi MA; Odunsi K; Olson SH; Orlow I; Orsulic S; Pearce CL; Pejovic T; Pelttari LM; Permuth-Wey J; Phelan CM; Pike MC; Poole EM; Ramus SJ; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Budzilowska A; Sellers TA; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Sucheston L; Tangen IL; Teo SH; Terry KL; Thompson PJ; Timorek A; Tworoger SS; Van Nieuwenhuysen E; Vergote I; Vierkant RA; Wang-Gohrke S; Walsh C; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Woo YL; Wu X; Wu AH; Yang H; Zheng W; Ziogas A; Coetzee GA; Freedman ML; Monteiro AN; Moes-Sosnowska J; Kupryjanczyk J; Pharoah PD; Gayther SA; Schildkraut JM
Carcinogenesis; 2015 Nov; 36(11):1341-53. PubMed ID: 26424751
[TBL] [Abstract][Full Text] [Related]
15. Basigin-2 is the predominant basigin isoform that promotes tumor cell migration and invasion and correlates with poor prognosis in epithelial ovarian cancer.
Zhao SH; Wang Y; Wen L; Zhai ZB; Ai ZH; Yao NL; Wang L; Liu WC; Chen BL; Li Y; Yang H
J Transl Med; 2013 Apr; 11():92. PubMed ID: 23566400
[TBL] [Abstract][Full Text] [Related]
16. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
[TBL] [Abstract][Full Text] [Related]
18. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Glasspool RM; Brown R; Gore ME; Rustin GJ; McNeish IA; Wilson RH; Pledge S; Paul J; Mackean M; Hall GD; Gabra H; Halford SE; Walker J; Appleton K; Ullah R; Kaye S;
Br J Cancer; 2014 Apr; 110(8):1923-9. PubMed ID: 24642620
[TBL] [Abstract][Full Text] [Related]
19. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.
Fotopoulou C; Vergote I; Mainwaring P; Bidzinski M; Vermorken JB; Ghamande SA; Harnett P; Del Prete SA; Green JA; Spaczynski M; Blagden S; Gore M; Ledermann J; Kaye S; Gabra H
Ann Oncol; 2014 Jan; 25(1):160-5. PubMed ID: 24318743
[TBL] [Abstract][Full Text] [Related]
20. Tim-3 expression defines regulatory T cells in human tumors.
Yan J; Zhang Y; Zhang JP; Liang J; Li L; Zheng L
PLoS One; 2013; 8(3):e58006. PubMed ID: 23526963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
